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Viral  vectors  used  in  heterologous  prime-boost  regimens  are  one  of  very  few  vaccination  approaches
that  have  yielded  signiﬁcant  protection  against  controlled  human  malaria  infections.  Recently,  protection
induced  by chimpanzee  adenovirus  priming  and  modiﬁed  vaccinia  Ankara  boosting  using  the  ME-TRAP
insert  has  been  correlated  with  the  induction  of potent  CD8+ T cell responses.  This  regimen  has  progressed
to  ﬁeld  studies  where  efﬁcacy  against  infection  has  now  been  reported.  The  same  vectors  have been  used
pre-clinically  to identify  preferred  protective  antigens  for use  in  vaccines  against  the  pre-erythrocytic,
blood-stage  and  mosquito  stages  of malaria  and  this  work  is reviewed  here  for  the  ﬁrst  time.  Such  antigen
screening  has  led to the  prioritization  of  the  PfRH5  blood-stage  antigen,  which  showed  efﬁcacy  against
heterologous  strain  challenge  in  non-human  primates,  and  vectors  encoding  this  antigen  are in  clinical
trials.  This,  along  with  the  high  transmission-blocking  activity  of  some  sexual-stage  antigens,  illustrates
well  the  capacity  of such  vectors  to  induce high  titre protective  antibodies  in  addition  to  potent  T cell
responses.  All  of the  protective  responses  induced  by these  vectors  exceed  the  levels  of the  same  immune
responses  induced  by natural  exposure  supporting  the  view  that,  for  subunit  vaccines  to achieve  even
partial  efﬁcacy  in  humans,  “unnatural  immunity”  comprising  immune  responses  of very high  magnitude
will  need  to be  induced.
©  2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  licenseThe progress of viral vectored vaccines for malaria through the
linical development pathway has accelerated considerably over
he past 5 years, in particular for chimpanzee adenovirus serotype
3 (ChAd63) and modiﬁed vaccinia Ankara (MVA) vectors encoding
E-TRAP, a pre-erythrocytic vaccine construct. ME-TRAP is a multi-
pitope (ME) string of known CD4+ and CD8+ epitopes from various
re-erythrocytic antigens, fused to thrombospondin-related adhe-
ion protein (TRAP). Clinical trials have demonstrated the ability
f these vectors to induce high frequencies of CD8+ T cells associ-
ted with the induction of useful levels of efﬁcacy in the controlled
uman malaria infection (CHMI) model [1] and a ﬁeld trial in a
alaria-endemic population [2]. Recent data from as yet unpub-
ished Phase I studies in children and infants in malaria-endemic
egions have shown favourable safety proﬁles in this target popu-
ation for a malaria vaccine. In this review, we describe the current
rogress of pre-clinical work at the Jenner Institute in Oxford
n the discovery of new antigens and vaccine constructs for the
∗ Corresponding author. Tel.: +44 0 1865 617622.
E-mail address: katie.ewer@ndm.ox.ac.uk (K.J. Ewer).
ttp://dx.doi.org/10.1016/j.vaccine.2015.09.094
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
pre-erythrocytic, erythrocytic and transmission stages of the par-
asite life cycle, for which viral vector technology is being used, as
well looking ahead at the progress of some leading malaria vectored
vaccine candidates.
1. Identifying novel protective malaria vaccine
components: pre-erythrocytic antigens
The availability of a full genome sequence of Plasmodium fal-
ciparum and the subsequent transcriptomic and proteomic [3,4]
analysis of rodent parasites [5] has opened new avenues for
research. Several genes expressed at the sporozoite and liver-stage
of P. falciparum have been identiﬁed that are potential targets for
a pre-erythrocytic subunit vaccine. The available genomic data in
combination with improved mass spectrometry analysis has facil-
itated the best proteome coverage to date for a pre-erythrocytic
stage of the human malaria parasite, in total 1991 P. falciparum
sporozoite proteins [6]. Sporozoite protein studies have helped
substantially in identifying many new potential candidates for a
pre-erythrocytic vaccine to block infection before the development
of clinical symptoms. However, only a minority of these have been
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ssessed for efﬁcacy to date, partly because there is no very efﬁ-
ient way to culture pre-erythrocytic stage parasites in vitro [7]. In
ddition, because P. falciparum cannot readily infect small animals,
creening P. falciparum target antigens pre-clinically is challenging
ithout the use of humanized DRAG or knock-out liver-chimeric
RG strains of mice [8,9].
Rodent malaria parasites are therefore generally used as models
o identify vaccine targets for protective immune responses against
uman malaria. Although a high level of orthology and homology
xists between the genes of Plasmodium species that infect rodents
nd humans [10,11], critical differences often exist in the sequence
nd structure between the encoded proteins. In addition, many
. falciparum malaria parasite genes are absent from rodent para-
ite genomes, making pre-clinical efﬁcacy studies unachievable in
urine models. Generation of transgenic rodent malaria parasites
xpressing P. falciparum genes can help to circumvent problems
rising from structural differences that exist between functional P.
alciparum and rodent malaria parasite orthologs. In addition, this
pproach broadens the options for analyzing P. falciparum-speciﬁc
roteins, in vivo [12]. There is increasing evidence that antigens
ther than the current two leading human malaria vaccine anti-
ens, PfCSP and PfTRAP, may  contribute to a protective immune
esponse [4,5,13,14] and it is likely that multiple antigens will be
eeded to reach very high levels of efﬁcacy.
We have recently screened a relatively large list of pre-
rythrocytic P. falciparum vaccine candidate antigens for protective
fﬁcacy [15]. These were identiﬁed from the literature, as well
s through database mining and bioinformatic analysis aiming to
dentify novel P. falciparum vaccine candidate antigens. These have
een incorporated into the ChAd63 and MVA  viral vectors and
mmunogenicity assessed in murine models. Thirteen P. falciparum
andidate antigens were initially chosen: LSA1, LSA3, CelTOS, UIS3,
SAP1, LSAP2, ETRAMP5, Falstatin, CSP, TRAP, HT, RP-L3 and SPECT-
. Each antigen had been shown to be either well expressed during
he liver-stage of infection; a target of cell-mediated immunity in
aturally exposed individuals or in those immunized with irradi-
ted sporozoites; or a homolog had been shown to be protective
n murine or non-human primate (NHP) studies. A novel chal-
enge model was used to assess the protective efﬁcacy of these
ew P. falciparum pre-erythrocytic vaccine candidates in mice using
ransgenic Plasmodium berghei parasites expressing P. falciparum
enes of interest, thus enabling efﬁcacy assessments in vivo. These
ransgenic parasites have been generated by introducing the genes
ncoding the antigens as an ‘additional copy’ into a neutral locus
f the P. berghei genome, either the Pb230p locus on chromosome
 or the Pbs1 locus on chromosome 12. Mice immunized with the
ifferent P. falciparum vaccine candidates were challenged by intra-
enous injection of the transgenic P. berghei sporozoites expressing
he cognate P. falciparum antigen, in order to determine protective
fﬁcacy conferred by the different vaccines after immunization.
All antigens were rank ordered in comparison to the two  lead-
ng malaria candidates PfCSP and PfTRAP using the same challenge
odel. Three antigens, PfLSA1, PfLSAP2 and PfSPECT-1, provided
etter protective efﬁcacy compared to PfCSP and PfTRAP in inbred
ALB/c mice. [15] Since different strains of mice are not equally sus-
eptible to malaria infection [16], and to minimize the risk of using
n inbred murine model as an indicator for the protective efﬁcacy
n humans, CD-1 outbred mice with diverse MHC  repertoires were
lso used, and again PfLSA1, PfLSAP2 and PfSPECT-1 showed bet-
er protective efﬁcacy compared to PfCSP and PfTRAP. Vaccination
ith PfUIS3, PfFalstatin, PfLSA3 and PfETRAMP-5 in BALB/c mice
rovided some degree of protection, manifest largely as a delay in
he time to parasitaemia, consistent with previous work with using
urine Plasmodium challenges [17,18]. Surprisingly, no protec-
ion was observed after vaccination with PfCelTOS despite previous
eports of cross-species protection in murine models [13,19]. (2015) 7444–7451 7445
We have also generated transgenic parasites expressing two  P.
falciparum antigens from the sporozoite- and liver-stages of the
life cycle, based on results from the initial efﬁcacy screening using
individual antigens. Speciﬁcally, two  ‘double transgenic’ parasites
have been constructed expressing different combinations of two
candidate antigens that showed the greatest protective efﬁcacy in
challenge experiments using the single gene transgenic P. berghei
parasites. The ﬁrst expressing the most promising two  novel can-
didates, PfLSA1 and PfLSAP2, and the second expressing the two
current leading pre-erythrocytic antigens, PfCSP and PfTRAP for
comparison. It has thus been possible for the ﬁrst time to assess
how best to combine multi-antigen vaccines and vaccination com-
binations using an in vivo model, and to generate better protection
than with a single-antigen immunization.
Of course the use of transgenic rodent parasites has limitations.
A murine model with a limited repertoire of MHC-restricted epi-
topes that may  not be representative of immunogenicity observed
in human populations. By assessing efﬁcacy and immunogenicity
in outbred mice strains, we  aim to reﬂect human immunity more
accurately. Interestingly, the efﬁcacy of the two  most promising
antigens, PfLSA1 and PfLSAP2, in CD-1 mice was comparable to that
in inbred mice. It is also possible that some antigens identiﬁed
as poorly immunogenic in these studies may  in fact be potently
immunogenic in humans. However the high cost of producing
vaccines requires some means of prioritizing antigens for Phase
I studies is required. Finally, the use of transgenic parasites will
inevitably affect the timing and magnitude of the expression of the
transgenic antigen as this will vary from expression in the native
parasite strain. Yet for antigens with no P. berghei ortholog, this
approach remains the only strategy to determine potential efﬁcacy
and is therefore a useful tool in pre-clinical vaccine development.
2. Identifying novel protective malaria vaccine
components: blood-stage antigens
Until recently, the P. falciparum blood-stage antigens that have
received the most attention include merozoite surface protein
1 (MSP1) [20,21], apical membrane antigen-1 (AMA-1) [22,23]
and MSP3 [24]. These proteins were prioritized in part due to
their immunogenicity either during active experimental infec-
tion [25–28] or immunization with non-viable puriﬁed merozoites
[29–31]. However, these vaccines have yielded disappointing (or
at least uncertain) results in clinical trials, likely because naturally-
acquired immunity to malaria owes its protective efﬁcacy to strong
responses against a broad range of antigens [32] and due to the
polymorphic nature of these antigens. Such breadth is difﬁcult
to recapitulate with a subunit vaccine. An alternative approach
involves deﬁning the parasite antigens that are most suscepti-
ble to immune attack, regardless of their immunogenicity during
natural infection. This approach was  pioneered by Rappuoli and
colleagues, who produced a library of more than 300 recombinant
proteins from Neisseria meningitides serogroup B, with which they
immunized rabbits to generate a large panel of antibody speciﬁci-
ties [33]. The activity of the antibody speciﬁcities in an in vitro
complement-mediated bacterial killing assay was used to deﬁne
the most susceptible protein antigens for inclusion in a multi-
component vaccine. The antigens identiﬁed in this screen are now
components in the multivalent vaccine Bexsero which was licensed
by the European Medicines Agency in 2013 [34]. This approach
faces a number of challenges when applied to Plasmodium spp.,
primarily the difﬁculty of expressing and purifying recombinant
protein, but also the need for much higher antibody titres to achieve
efﬁcacy against malaria compared to meningitis. For example, an
attempt to bacterially express 1000 proteins from P. falciparum
resulted in the expression of just 63 soluble proteins [35], while
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 separate attempt to bacterially express 95 P. falciparum proteins
ielded just 5 soluble recombinants [36]. Recombinant viral vectors
an be used to circumvent this protein production hurdle and sim-
lify the task of obtaining high-titre, antigen-speciﬁc antibodies.
ethods for the construction of recombinant viral genomes, trans-
ection of genomes into complementary cell lines, growth of virus
nd subsequent puriﬁcation are now well established and the mate-
ials are commercially available. Advances in production methods
ow mean that adenoviruses expressing transgenes whose prod-
cts are deleterious to viral growth can also be produced [37].
iral vectors therefore offer a useful ‘one-size-ﬁts-all’ solution
o the difﬁculties of expressing recombinant proteins and have
een shown to induce functional antibodies with growth inhibitory
ctivity [38]. Recent work undertaken at the Jenner Institute has
enerated viral vector pre-clinical vaccine candidates encoding
4 different proteins found on the surface of P. falciparum mero-
oites, including full-length constructs of the reticulocyte-binding
rotein homolog 5 (PfRH5) [39], the PfRH5-interacting protein
PfRipr) [40] and rhoptry-associated protein 1 (PfRAP1) (unpub-
ished data). In all cases these vaccines have elicited antibodies
apable of recognizing native schizont protein in an immunoﬂu-
rescence assay. PfRH5 is of particular interest because previous
eports that used recombinant protein fragments based on PfRH5
s the immunogen did not have any signiﬁcant neutralizing activity
41,42]. By contrast, viral vectors elicited potent neutralizing poly-
lonal antibodies [39], and have since been used to raise the most
otent neutralizing monoclonal antibodies (mAbs) yet described
as measured by the assay of GIA [40] and induced signiﬁcant efﬁ-
acy in a NHP model of blood-stage P. falciparum infection [43].
he ChAd63 and MVA  vectors encoding PfRH5 have since entered
 Phase Ia clinical trial in Oxford (Clinicaltrials.gov NCT02181088).
While viral vectors offer considerable advantages over protein-
n-adjuvant as a method for raising antigen-speciﬁc antibodies, it is
mportant to be mindful of some caveats. These arise largely from
he fact that viral vectors cause protein expression to occur in situ
n the immunized organism, meaning that it is impossible to fully
haracterize the immunogen that is produced. In silico approaches
nd in vitro infection assays can to an extent predict protein folding,
uccessful trafﬁcking through the secretory pathway, polypeptide
leavage and post-translational modiﬁcations such as glycosyla-
ion, but the actual course of events in the immunized mammalian
ell cannot easily be monitored in real time. On the other hand
rotein-in-adjuvant vaccines face similar difﬁculties, particularly
nce formulated in adjuvant. All in all, the relatively straight-
orward production and reliable immunogenicity of viral vectors
akes them an excellent tool for the generation of antibody speci-
cities and the deﬁnition of parasite antigens that are susceptible
o antibody attack.
. Identifying novel protective malaria vaccine
omponents: transmission-blocking antigens
In a relatively new programme of work at the Jenner Insti-
ute, we have expressed leading transmission-blocking vaccine
andidate antigens from ChAd63 and MVA  viral vectors. Initial
mmunization studies with adenovirus (ChAd63 or human serotype
 adenovirus, AdHu5) delivery vectors followed by MVA  boosting,
licited anti-Pfs25 antibodies capable of blocking transmission in
embrane-feeding assays [44]. Subsequently, we used this het-
rologous prime-boost vaccination regimen to directly compare
he abilities of ﬁve leading sexual-stage antigens (Pfs25, Pfs230C,
fHAP2, Pfs48/45, and AgAPN1) to induce transmission-blocking
ntibodies. In this screen Pfs25, a 25-kDa surface antigen of zygotes
nd ookinetes was the most potent immunogen followed by a
ragment of Pfs230 [45]. Anti-Pfs25 antibodies are functional in (2015) 7444–7451
the ex vivo standard membrane feeding assay (SMFA) and com-
pletely block the development of P. falciparum in the mosquito.
The antibodies also block the development of ﬁeld isolates (from
gametocyte donors in Burkina Faso) of P. falciparum.  Most recently,
we have fused Pfs25 to IMX313, a new heptamerization technol-
ogy, leading to the expression of a heptamer from viral-vectors
(ChAd63 and MVA). Immunization with viral vectors expressing
Pfs25-IMX313 shows about 10-fold greater immunogenicity and
signiﬁcantly better transmission-blocking efﬁcacy in membrane
feeding assays than Pfs25 alone [46]. In other studies elsewhere,
immunization with the AdHu5 vector expressing Pvs25 elicited
antibodies which signiﬁcantly reduced the average oocyst numbers
per mosquito when tested against gametocytes from Plasmodium
vivax infected volunteers [47]; whilst antisera from mice vaccinated
with baculovirus vectors (baculovirus dual-expression system)
expressing both Pvs25 and PvsCSP also elicited antibodies that gave
signiﬁcant transmission-blocking activity [48].
In terms of clinical trials, in 1996 volunteers were primed with
a highly attenuated vaccinia viral vector expressing seven genes
from P. falciparum (denoted NYVAC-Pf7), including Pfs25, followed
by a boost of Pfs25 recombinant protein. The volunteers devel-
oped low level anti-Pfs25 antibodies which exhibited incomplete
transmission-blocking activity [49]. A Phase Ia human clinical trial
will be initiated in Oxford in 2015 to test viral-vectored vaccines
expressing Pfs25-IMX313 as part of an EU funded project (Multi-
MalVax, see www.multimalvax.eu).
4. Clinical evaluation of viral vectored vaccines for malaria
Induction of CD8+ T cells will be a crucial component of vaccine
platforms that aim to induce sterile protection against the malarial
liver-stage [50]. Pre-clinical studies in mice and NHPs demonstrate
that subunit platforms based on highly potent adenoviruses and
MVA regimens elicit CD8+ T cell responses of high magnitude. This
will be critical for effective clearance of all parasitized hepato-
cytes in order to prevent blood-stage parasitemia and associated
morbidity, and mortality. Recent Phase I/II studies have translated
pre-clinical immunogenicity ﬁndings with these viral vectors in
order to understand vaccine-induced efﬁcacy against malaria infec-
tion in humans, as summarized in Table 1.
4.1. AdHu5 CSP/AMA-1
Research at the Naval Medical Research Center in the USA led
to the development of a multi-stage vaccine that combined two
AdHu5 vectors containing CSP and AMA-1 (NMRC-M3V-Ad-PfCA).
A Phase I/IIa study demonstrated that the vaccine was  safe and
well tolerated, but did not induced sterile protection in any vol-
unteers [51,52]. Two  out of eleven vaccinees showed signiﬁcant
delay to patency. Notably, AdHu5 immunization induced strong
CD8+ T cell responses against both CSP and AMA-1, largely com-
posed of monofunctional IFN producers [52]. This was the ﬁrst
demonstration of a malaria vaccine inducing predominantly CD8+
T cells, and not CD4+ T cells, which are less directly related to
protection.
4.2. DNA – AdHu5 CSP AMA-1
Heterologous prime-boost approaches have been shown to
increase durability of CD8+ T cell responses and improve protection
in animal models over single vaccination models [53–55]. This
strategy circumvents the problem of vaccine-induced antibodies
against the vector dampening boosting of immune responses upon
repeated homologous vaccinations. Based on poor efﬁcacy results
with AdHu5 alone [56], the authors investigated the effect of a
DNA prime prior to AdHu5 administration [57]. Vaccination with
K.J. Ewer et al. / Vaccine 33 (2015) 7444–7451 7447
Table  1
Summary of clinical trials employing viral vectors for malaria since 2010.
Source: https://clinicaltrials.gov. Accessed 13th April 2015. *All immunization regimens were administered intramuscularly (IM), unless otherwise noted. Blue = Liver-stage
a iparu
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p
hntigen. Purple = Liver/Blood-stage antigen. Pink = Blood stage antigen. All are P. falc
NA AdHu5 encoding CSP and AMA-1 was safe, immunogenic
nd induced sterile protection in 4/15 volunteers (27% efﬁcacy).
LISPOT responses to AMA-1 were signiﬁcantly associated with
rotection (p = 0.019). Although encouraging, this level of efﬁcacy
id not differ signiﬁcantly from the control group as assessed by
he standard Kaplan-Meier, log rank test, analysis. AMA-1-speciﬁc
FN+ CD8+, but not CD4+, T cells were associated with the observed
rotection (p = 0.0492). Three of four sterilely protected showed
igher effector to central memory CD8+ T cells to AMA-1 comparedm trials unless indicated otherwise [83–91].
to non-protected volunteers (Ad5 or DNA/Ad5). Class I epitopes
restricted by A*03 or B*58 within AMA-1 appeared important
for protection in three of four volunteers [58]. The role of CSP in
protection induced by DNA/Ad5 immunization is unknown, but
changing the vector or adding additional malaria antigens may
improve efﬁcacy. Of note, administration of DNA  plasmids alone
expressing pre-erythrocytic-stage epitopes and administered via
electroporation (EP1300) were assessed in a Phase I clinical trial in
2012 [59].
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.3. ChAd63 MVA  ME-TRAP
Pre-existing neutralizing antibodies (nAbs) against human ade-
oviruses may  interfere with protection induced by AdHu5 alone
r DNA prime – AdHu5 boost vaccination. [51,57].
Simian-derived vectors such as ChAd63 should circumvent
ost naturally-acquired anti-vector immunity that could diminish
denovirus-induced T cell responses [60]. The vaccine insert ME-
RAP elicits protective CD8+ T cell responses in mice [54,61] and
howed promising immunogenicity in NHPs [62]. Based on encour-
ging safety data in humans [63], a Phase I/IIa CHMI trial assessed
he efﬁcacy of ChAd63 ME-TRAP alone or followed by a boost with
VA ME-TRAP in malaria-naïve adults [1].
The clinical ﬁndings were very encouraging. Prime-boost vacci-
ation with ChAd63-MVA induced T cell responses that were 5–10
old higher than earlier subunit regimens with the same antigenic
nsert as measured by ex vivo IFN ELISPOT [64,65]. Moreover,
ellular immunity was of considerable breadth, as all volunteers
ecognized over half of the peptide pools spanning TRAP. The
uality of T cell responses also dramatically shifted from earlier
latforms. Unlike ﬁrst- and second-generation viral vectors, such
s fowlpox (FP9)-MVA, which predominantly induced CD4+ T cells
64,65], the ChAd63-MVA combination regimen induced a high
roportion of cytokine-producing CD8+ T cells. While no protection
as induced with ChAd63 alone, the MVA  boost clearly improved
rotective efﬁcacy: 3/14 volunteers were sterilely protected and
/14 showed a two-day delay in time to patent parasitemia, the lat-
er representing a 95% reduction in liver parasite burden. Sensitive
PCR analysis revealed reduction of parasite density emerging from
he liver over second and third parasite replication cycles, which
egatively correlated with time to parasitemia. This provides fur-
her evidence of biological effect of the vaccine on malaria infection.
verall, ChAd63-MVA provided a total efﬁcacy (delay plus sterile
rotection) of 58% (8/14), marking the ﬁrst study to show statisti-
ally signiﬁcant high-level, heterologous or homologous protection
nduced by a prime-boost regimen.
Duration of protection is as yet unclear as CHMI was performed
wo weeks following the ﬁnal vaccination to assess short-term
fﬁcacy. Encouragingly, ELISPOT responses were detected up to
00 days post-adenovirus administration. Three sterilely pro-
ected volunteers were re-challenged eight months after their last
mmunization: one was sterilely protected again and two showed
igniﬁcant delay to patency, encouraging larger studies to further
ssess durability of protective immunity.
Analysis of immune responses revealed that CD8+ T cells secret-
ng IFN, but not IL-2 or TNF, at time of challenge correlated
trongly and signiﬁcantly with protection. This is line with pre-
ious studies assessing a similar construct in mice [54] and an
bservation in the DNA-AdHu5 trial where there was an associ-
tion between frequency of the same CD8+ T cell population and
terile protection [57]. Notably, antibodies targeting TRAP did not
ppear to play a role. Pre-clinical studies in mice and NHPs have
emonstrated that cellular immunity is critical for sterile protec-
ion against malaria liver-stage infection and should be sufﬁcient
n the absence of antibodies [66–68]. It is hypothesized that IFN
ecretion by CD8+ T cells and other innate immunity contributors
uch as NK and  T cells mediate killing of infected hepatocytes
69,70]. However, the quality and requirements of protective CD8+
 cells appear to vary greatly by immunization regimen and species
69,71]. In-depth characterization of CD8+ T cells induced by viral
ectors in humans will be necessary to elucidate further a mecha-
ism of protection.ChAd63-MVA vaccination induced greater immunogenicity and
fﬁcacy compared to DNA or FP9 priming with the same anti-
enic insert [64,65]. Only 9/38 volunteers showed any efﬁcacy
ith either of these earlier regimens, and in the overwhelming (2015) 7444–7451
majority of subjects, this manifested as delay to patency. This study
also demonstrated a substantial improvement in antigen-speciﬁc
CD8+ T cell frequency over DNA-AdHu5 CSP-AMA-1 vaccination
[57]. The differential results of immunogenicity and efﬁcacy may
be caused by a number of reasons. First, pre-existing nAb titres
against the ChAd63 vector were low. Furthermore, they did not
correlate with induced T cell responses, reducing earlier concerns
of anti-vector immunity in human adenovirus vaccination. Second,
simian adenoviruses induce predominantly CD8+ T cell responses
compared to FP9 and DNA priming [64,65]: CD8+ T cells have been
shown to directly kill infected hepatocytes in vitro [72]. Third,
differential innate immunity elicited by viral vectors may play a
critical role in shaping vaccine-induced T cells [73,74]. Finally, the
T cell responses induced by any adenovirus boosted by MVA  are of
substantially greater magnitude in humans than DNA- adenovirus
prime-boost regimens.
Promising strategies tested in malaria-naïve individuals may fail
to generate high-level immunogenicity and efﬁcacy when deployed
in endemic regions [64,65,75,76]. The role of immunosuppres-
sion caused by recurrent parasitemia or interference of naturally
acquired T cells and/or antibodies in vector-induced immunity is
unknown. Accordingly, a Phase IIb ﬁeld study was  designed to
assess the protective efﬁcacy of this regimen in adults with previous
malaria exposure [2]. 120 Kenyan male volunteers were admin-
istered either ChAd63-MVA ME-TRAP or the rabies vaccine and
monitored for eight weeks for malaria infection. All volunteers
were given anti-malarials after vaccination and prior to the PCR
monitoring period in order to clear any residual parasites [77].
Immunogenicity was broadly comparable to that seen in UK vac-
cinees, if a little lower in magnitude. ChAd63 priming induced T cell
responses approximately 5-fold greater than those induced by DNA
or FP9 priming in endemic regions [75,76]. Immune responses were
biased towards IFN+ CD8+ T cells and detected up to six months
post-vaccination, albeit by this time point they had fallen to a quar-
ter of the peak levels. Similarities in the quantity and quality of T
cell responses between exposed adults vs. malaria-naïve suggest
that vaccination did not boost naturally-acquired immunity [78].
Interestingly, T cell responses were biased to a single TRAP peptide
pool. Whether this reﬂects an enrichment of certain HLA alleles in
the region or a mechanism of protection is unclear.
Protective efﬁcacy was  assessed by time to infection as mea-
sured by a sensitive PCR assay. In the year that the efﬁcacy was
assessed, an unexpected spike in rainfall curtailed transmission
rates and decreased the overall number of infections, making it
difﬁcult to assess efﬁcacy beyond the initial weeks of monitor-
ing. However, Cox-regression analysis, used to analyze the primary
endpoint of the trial, found that the vaccine reduced the risk of
infection by 67% (95% CI 33–88%), p = 0.002 during the 8 weeks
of monitoring. Furthermore, risk of high parasitemia (>10 par-
asites/mL, a secondary endpoint) was reduced by 82% (95% CI
46–94%), p = 0.002. The overwhelming majority of breakthrough
infections were acquired during the PCR monitoring period, and
were not residual or recrudescent. SNP genotyping analysis demon-
strated that only 1/19 samples pre vs. post treatment were identical.
Interestingly, once again a T cell correlate of vaccine efﬁcacy was
identiﬁed with this approach, in this case the ex vivo IFN ELISpot
response to the immunodominant pool of TRAP peptides.
Efﬁcacy in this study was  much higher than an earlier Phase IIa
CHMI study. There are a number of possible explanations. Firstly,
there is a lower intensity of challenge inoculum in the ﬁeld. CHMI
requires the bites of ﬁve heavily infected mosquitoes to evaluate
efﬁcacy compared to probably a single bite in the ﬁeld. In addition,
transmission was  unexpectedly low for the study area, decreasing
the parasite liver burden and the threshold for sterile immunity.
Secondly, the atovaquone component of treatment prior to the
PCR monitoring period has a relatively long elimination half-life.
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 possible prolonged biological effect of this drug may  explain
hy all infections were of low intensity. It is difﬁcult to ascertain
he variable effect of antimalarials on efﬁcacy over time since the
tudy was cut short by rains. Finally, naturally-acquired host immu-
ity may  have helped to clear merozoites emerging from the liver,
ossibly creating a synergistic effect between vaccine-induced and
aturally-acquired responses.
.4. Combination vaccine approaches
The current leading malaria candidate, RTS,S/AS01, has com-
leted Phase III efﬁcacy trials in the target population of children
nd infants in sub-Saharan Africa [79]. Efﬁcacy data are now avail-
ble on a median follow-up time of 36 months for young infants
eceiving their ﬁrst dose of RTS,S/AS01 at 6–12 weeks of age
“infants”), and for the older infants and children who received their
rst vaccination at 5–17 months of age (“children”). Efﬁcacy against
linical malaria in infants was 18% [12–24% CI] and against severe
alaria clinical malaria, a non-signiﬁcant 10% [−18% to 32%]. So, in
his group that received other Expanded Programme on Immuniza-
ion (EPI) vaccinations, overall efﬁcacy was modest. This could be
mproved to 26% (clinical) and 17% (severe malaria) by administer-
ng a booster vaccination dose at month 20. In the older age group
f children, efﬁcacy against clinical malaria over 48 months median
ollow-up was 28% increasing to 36% will a booster dose; however,
fﬁcacy against severe malaria was only 1% without a booster, and
2% with the booster dose.
These modest levels of protection over 3–4 years conceal much
igher levels of efﬁcacy in the ﬁrst months after immunization that
re associated with very high levels of antibody to the central repeat
f the CS protein. These levels of hundreds of ELISA Units per mL
all over time and protection wanes. One approach to attempt to
mprove durability and overall efﬁcacy could be to add a viral vec-
or encoding ME-TRAP to RTS,S/AS01 in a combination approach,
nd Phase I/IIa trials of this approach are in progress as a collabo-
ation between Oxford and GSK Vaccines. Moreover, once efﬁcacy
s achieved with other stage components, e.g. PfRH5, one strategy
ill be to attempt to combine several partially protective vaccine
omponents into a higher efﬁcacy multi-stage vaccine.
.5. “Unnatural immunity”
It is striking that the levels of antibody response to CS protein
nduced by RTS,S/AS01 are about 100 fold greater after immu-
ization than is ever observed pre-vaccination or after natural
alaria exposure. Similarly, the levels of T cell response induced
y viral vectors to TRAP are about 100-fold greater than those
ound after a lifetime of natural exposure to malaria. But these very
igh levels of immune response are required for partial protection
gainst malaria. Interestingly, immune responses to the promis-
ng blood-stage vaccine candidate antigen PfRH5 are also modest
fter natural exposure so that, again, the current PfRH5 vaccine
andidates should induce “unnatural” levels of immunity. Finally,
atural immune responses to the leading transmission-blocking
andidate antigen, Pfs25, are minimal (or non-existent due to lack of
ntigen expression in the mammalian host) so that again vaccina-
ion induces immune responses that are never observed naturally.
learly, modern vaccine technology allows immune responses that
re “better than nature” to be induced, but an on-going challenge
ill be to identify these key responses and maintain protective
evels to provide durability of efﬁcacy.
In addition to demonstrating the impressive immunogenicitynd level of efﬁcacy attainable with viral vectors, work is on-going
o further demonstrate safety of these relatively new vectors in
iverse populations. These include children and infants in African
ountries including young infants receiving simultaneously other
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EPI vaccines. To date over a thousand subjects have been immu-
nized with ChAd vectors for malaria with a very good safety record
and even larger numbers have been immunized with MVA vec-
tors encoding malaria antigens. This goal of safety assessment is
supported by the increasingly widespread use of other simian ade-
novirus and MVA  vectors for vaccination against tuberculosis [80],
HIV [81], Ebola [82] and other diseases.
Conﬂict of interest: None of the authors has conﬂicts of interest.
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